Skip to content

Study · Other design · n = 2,067 · 2012

11 results

Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.

Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW

Postgraduate medicine1 Jul 2012Cited by 45 (Europe PMC)

PMID22913891 (opens in a new tab)DOI10.3810/pgm.2012.07.2567 (opens in a new tab)PepBankPUB-22913891
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanOther designEfficacy outcome

    In pooled patients with type 2 diabetes, exenatide improved glycated hemoglobin from baseline across all demographic groups.

    In plain wordsIn pooled patients with diabetes, blood sugar marker levels improved during exenatide treatment across all demographic groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlycated hemoglobin across demographic groups
    Study

    n = 2,067

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Source sentences

    Summary
    All groups experienced significant improvements in glycated hemoglobin, fasting plasma glucose levels (other than black patients, who had a relatively low baseline fasting plasma glucose level), and body weight from baseline to endpoint.
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  2. 02HumanOther designEfficacy outcome

    In pooled patients with diabetes, exenatide reduced body weight from baseline across all demographic groups.

    In plain wordsIn pooled patients with diabetes, body weight fell during exenatide treatment across all demographic groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight across demographic groups
    Study

    n = 2,067

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Source sentences

    Summary
    All groups experienced significant improvements in glycated hemoglobin, fasting plasma glucose levels (other than black patients, who had a relatively low baseline fasting plasma glucose level), and body weight from baseline to endpoint.
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  3. 03HumanOther designSafety outcome

    In pooled patients with diabetes receiving exenatide, nausea occurred in 38.6%.

    In plain wordsIn pooled patients with diabetes receiving exenatide, 38.6% had nausea.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableNausea
    Study

    n = 2,067

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Measurements

    Nausea
    38.6%
    exenatide

    Source sentences

    Summary
    The most common adverse events overall were nausea (38.6%), hypoglycemia (28.4%), and vomiting (14.0%).
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  4. 04HumanOther designSafety outcome

    In pooled patients with diabetes receiving exenatide, hypoglycemia occurred in 28.4%.

    In plain wordsIn pooled patients with diabetes receiving exenatide, 28.4% had low blood sugar.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableHypoglycemia
    Study

    n = 2,067

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Measurements

    Hypoglycemia
    28.4%
    exenatide

    Source sentences

    Summary
    The most common adverse events overall were nausea (38.6%), hypoglycemia (28.4%), and vomiting (14.0%).
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  5. 05HumanOther designSafety outcome

    In pooled patients with diabetes receiving exenatide, vomiting occurred in 14.0%.

    In plain wordsIn pooled patients with diabetes receiving exenatide, 14.0% had vomiting.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableVomiting
    Study

    n = 2,067

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Measurements

    Vomiting
    14%
    exenatide

    Source sentences

    Summary
    The most common adverse events overall were nausea (38.6%), hypoglycemia (28.4%), and vomiting (14.0%).
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  6. 06HumanOther designEfficacy outcome

    In pooled patients with diabetes, exenatide improved fasting glucose from baseline in all demographic groups except black patients.

    In plain wordsIn pooled patients with diabetes, fasting blood sugar improved during exenatide treatment in all demographic groups except black patients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedFasting plasma glucose across demographic groups
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Source sentences

    Summary
    All groups experienced significant improvements in glycated hemoglobin, fasting plasma glucose levels (other than black patients, who had a relatively low baseline fasting plasma glucose level), and body weight from baseline to endpoint.
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  7. 07HumanOther designEfficacy outcome

    In pooled patients with diabetes, most demographic groups had significant systolic blood pressure improvements during exenatide treatment.

    In plain wordsIn pooled patients with diabetes, upper blood pressure improved during exenatide treatment in most demographic groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Source sentences

    Summary
    Most groups had significant improvements in systolic blood pressure.
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  8. 08HumanOther designEfficacy outcome

    In pooled patients with diabetes, all age, sex and diabetes-duration groups had lipid improvements during exenatide treatment, except HDL cholesterol.

    In plain wordsIn pooled patients with diabetes, lipid levels improved during exenatide treatment across age, sex and diabetes-duration groups, except HDL cholesterol.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedLipids by age, sex and diabetes duration
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Source sentences

    Summary
    All of the age, sex, and duration of diabetes groups experienced significant improvements in lipid levels (other than high-density lipoprotein cholesterol).
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  9. 09HumanOther designEfficacy outcome

    In pooled exenatide-treated patients with diabetes, lipid improvements generally occurred in whites and Asians, but not blacks and Hispanics.

    In plain wordsIn pooled exenatide-treated patients with diabetes, blood fats generally improved in whites and Asians, but not blacks and Hispanics.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedLipids by race
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Source sentences

    Summary
    Whites and Asians generally experienced significant improvements in lipid levels, whereas blacks and Hispanics did not.
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.
  10. 10HumanOther designEfficacy outcome

    In pooled exenatide-treated patients with diabetes, lipid levels generally improved across BMI groups.

    In plain wordsIn pooled exenatide-treated patients with diabetes, blood fats generally improved across body mass index groups.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedLipids by BMI
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 μg twice dailyAs given in this study (human).

    Source sentences

    Summary
    Significant improvements in lipid levels were generally seen across BMI groups.
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 11HumanNot a test of Exenatide (exendin-4) aloneOther designSafety outcome

    In pooled exenatide-treated patients with diabetes, hypoglycemia was more common with concomitant sulfonylurea than without it.

    In plain wordsIn pooled exenatide-treated patients with diabetes, low blood sugar was more common with sulfonylurea than without it.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHypoglycemia with concomitant sulfonylurea
    Study

    n: not reported in source

    Comparator
    exenatide without sulfonylurea
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Hypoglycemia was more common overall in patients who were taking a concomitant sulfonylurea than it was in patients who were not.
    1 context sentence
    Summary · context
    This post hoc analysis included data from 16 randomized controlled trials in which patients with type 2 diabetes mellitus were treated with 10-μg exenatide BID.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials12

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

12 trials · 12 completed · 8 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00765817

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

AstraZenecan = 261Oct 2008 to Jan 2010

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 24 Oct 2016
CompletedPhase 3Results postedNCT00577824

Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

AstraZenecan = 181Jan 2008 to Nov 2008

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 9 Apr 2015
CompletedPhase 3Results postedNCT00603239

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

AstraZenecan = 165Jan 2008 to Jul 2009

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 7 Apr 2015
CompletedPhase 3Results postedNCT00434954

Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

AstraZenecan = 494Feb 2007 to Jun 2009

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 7 Apr 2015
CompletedPhase 3Results postedNCT00375492

Effect on Weight Loss of Exenatide Versus Placebo

AstraZenecan = 196Sept 2006 to Feb 2008

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 7 Apr 2015
CompletedPhase 3NCT00381342

Safety and Efficacy of Exenatide as Monotherapy

AstraZenecan = 233Sept 2006 to Sept 2007

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 23 Feb 2015
CompletedPhase 3Results postedNCT00360334

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

AstraZenecan = 235Jun 2006 to Apr 2008

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 7 Apr 2015
CompletedPhase 3Results postedNCT00082407

Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin

AstraZenecan = 505Nov 2003 to Jul 2008

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 7 Apr 2015
CompletedPhase 3Results postedNCT00082381

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

AstraZenecan = 551Jun 2003 to Jul 2008

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 7 Apr 2015
CompletedPhase 3NCT00035984

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

AstraZenecan = 734May 2002 to Aug 2003

Diabetes Mellitus, Non-Insulin-Dependent

Trial pageClinicalTrials.govUpdated 24 Feb 2015
CompletedPhase 3NCT00039013

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

AstraZenecan = 336Mar 2002 to Jun 2003

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 24 Feb 2015
CompletedPhase 3NCT00039026

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

AstraZenecan = 377Feb 2002 to Aug 2003

Diabetes Mellitus, Non-Insulin-Dependent

Trial pageClinicalTrials.govUpdated 24 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.